Fevertree Drinks Share Discussion Threads

[christh] 27/2/2018 10:20

you did.
and also said you will not harass me any more!

But little do I care about your comments or your views.

I have said that this is going to £28 and it will hit £28 probably around or before
the 13 March.
That will be a milestone.
I do expect to carry on to £30 and beyond , you can not deny success for this company.

This weekend and next weekend will have the press,media forecasting and speculating about the results.

As for the price at this level is another opportunity to "Buy".
The price will recover this afternoon.

[villarich] 27/2/2018 10:04

When did I say you were filtered?

[christh] 27/2/2018 09:55

Villarich
I am filtered, ain't I?

[villarich] 27/2/2018 09:35

Every time you put out one of these guesses, the price drops.

[christh] 27/2/2018 08:09

Now that has broken £26 it will go higher to £28.
Today will test £26.60

All in my opinion.

[orissander] 26/2/2018 16:40

Too risky to sell and buy following a chart, one day you will miss a +20%... and all the effort will be futile.
I am waiting patiently with a gin tonic next month with a oversized stock position. :D

[minnerva] 26/2/2018 16:34

Wetdream i agree, £25 now being hard to dip under. sold last week & managed to buy back with extras this morning at 24.96, v pleased to have done so in the nick of time

[wetdream] 26/2/2018 15:31

MMs basically playing with the share price on v low volumes.

[christh] 26/2/2018 14:23

It might test £26 today.
Great demand for the shares

[wetdream] 26/2/2018 14:16

£25.00 resistance now becomes support?
At least till results.

[christh] 26/2/2018 09:47

According to brokers Fevr is a strong "BUY"

Look under broker forecasts

[christh] 26/2/2018 09:19

FEVR...... More here from broker Morgan Stanley.......

With high growth potential and attractive returns, we see Fever-Tree as a unique opportunity in European Staples. Our channel checking and proprietary industry model suggest the premium mixers market could triple in the next 5 years with
Fever-Tree well placed to capitalise on this growth.

Fever-Tree's performance to date has been impressive. The company effectively created the premium mixers category, giving consumers more choice and a higher quality product, with better cash margins for the on-trade and a high rate of sales in the retail channel. Drawing on our extensive channel checking, we expect the premiumisation of mixers to continue and see Fever-Tree as well placed to capitalise on this growth despite increased competition.

The penetration of premium mixers is currently 9% of the total mixers market versus 33% for premium spirits, the closest proxy for mixers. Our industry model assumes further penetration of premium mixers, driving a ~20% CAGR 2017-25 across Fever-Tree's core markets. This growth underpins our forecasts for 23% revenue CAGR, 20% EBITDA CAGR and 20% EPS CAGR between FY17-20

Fever-Tree employs an asset light business model. It does not own its manufacturing and relies on third parties for distribution. The group thus has impressive returns on invested capital, which we estimate to grow sustainably going forward from 43% in FY16 to 63% by FY20, while FCF should double.

We think the growth potential for Fever-Tree is underappreciated (particularly by sell-side consensus), and we view Fever-Tree's asset light, high returns business model favourably. We set our, £30.00 price target based on our DCF methodology, with the risk reward skewed to the upside, in our view. Increased competition or a slower penetration of premium mixer than we are currently expecting are key risks to our rating and price target.

[christh] 26/2/2018 08:45

Started to push higher but dropped a bit because of weak trading but a great opportunity for a big rise on the 13 March (about 10 working days away).

I expect a good recovery and a push to £26 as the share price was aiming higher ending at £25.31 last fiday.

Buy and forget it, wake up on the 13 March for the big bonanza.

[bamboo2] 25/2/2018 19:23

Fall off in volume. Flag pattern? Potential turns noted 26/2/2018, 2-5/3/2018, 8/3/2018
[edited dates from 2[feb] to 3[mar]]

[discodave4] 23/2/2018 15:49

Have seen this rated in the past in excess of 60x, has been in the low 70's so feel general market sentiment has changed rather than company specific (but wtfdik).DD

[villarich] 23/2/2018 13:45

Good stuff. You need to look at growth rates as well as the financial statements. Fever is a good example of a company where the financial statement is solid but the share price is driven by future growth expectations. If it wasn't then the share price would be a lot lower than it is now because it would be on a lower multiple of EPS.

[dannyt90] 23/2/2018 13:42

I read the naked trader and found that very helpful as a starter to buying shares.I tend to dwell more into the financial statements of companies rather then the news or hear say. I find that much more satisfying and reassuring knowing that I've chosen a share I've done research on and confident in the company. Hence what bought me to Fever Tree!

[orissander] 23/2/2018 13:25

25£ before ER and 28£+ after

[christh] 23/2/2018 10:20

FEVERTREE DRINKS

Fevertree Drinks is in a "unique" position to capitalise on the 'premiumisation' or 'gin-naissance' trends in the drink industry, analysts believe, leading to rumours on Friday that the company may be a takeover target.

Shares in Fevertree were boosted by reports that consumer goods colossus Unilever was looking to buy Fevertree, while analysts at Jefferies also began coverage of the London-listed company with a 'buy' recommendation.

Unilever will try to snap up the mixers maker for "at least £28 per share", the Telegraph reported, with rumours rising after Fevertree appointed Kevin Havelock, Unilever’s global president of refreshment, as a non-executive director last week.

Jefferies, on Friday began coverage of the upmarket mixers maker with a 3,000p target price, said the company was a "unique asset that offers a leveraged play on premiumisation trends in spirits in a sub-category where there is a disconnect between premium spirits and mixers".

The structural driver of the consumer trend towards more 'premium' spirits sees people seeking to drink 'better not more' and prepared to pay a premium for high-quality brands.

London-listed Fevertree offers a "better way to participate in the gin-naissance than the spirits majors given craft/fragmentation trends", with the trend having not yet spread from premium spirits to mixers.

"We see an on-going disconnect between growth in the large premium spirits category and an increasingly commoditised mixers category. The mixers category remains ripe for mass disruption, in our view."

Jefferies analysts see growth in tonics driving a standalone value per share of 2,500p and then shake and stir in a further 500p on what they see as a 20% probability Fevertree can capitalise on the non-tonic mixers category.

[christh] 23/2/2018 10:03

FY17 expectations
------------------------------------------------
Reflecting the continued strong performance through to the end of the year, the Board expects that the outcome for the full year will be comfortably ahead of market expectations.

Fever-Tree will announce its Preliminary Results on 13th March 2018.

Commenting on today's announcement, Tim Warrillow, Co-founder and CEO of Fever-Tree said:

"I am very proud of our performance in 2017 which has seen Fever-Tree end the year as the number one mixer brand at UK retail. Our pioneering approach and commitment to providing consumers with the highest quality range of mixers continues to capture peoples' imagination and is transforming the wider UK mixer category which as a result is now the fastest growing category across the soft drinks sector.

While we have seen strong growth across all regions, our performance in the UK over the Christmas period was once again exceptional. Our growing range of mixers and formats are appealing not only to our loyal customers but also bringing consumers back to the category and importantly attracting a new younger audience.

There is clear evidence that the same trends of premiumisation and mixability that we've previously highlighted are accelerating and we are increasingly excited by the global opportunity this presents particularly as we transition to our own operations in the US."

Download the report here (PDF)

[villarich] 23/2/2018 09:56

Spot on. 60x for me this year and down to 50x next. Fever tree needs to transition from growth share to steady stalwart over time and therefore the market won't pay 60x forever

[sogoesit] 23/2/2018 09:37

Meanwhile... ;-) £25'ish is looking hard to break.

My conclusion is market finds this valuation to be at limit. I think Villa mentioned, and I agree, that is probably 60x 2017 EPS of 40p'ish.
The market doesn't seem to want to bet on next year's EPS... yet.
Until we get results on 13 March which may indicate better than expected growth it's a bit of a hiatus for the time being imv.

[villarich] 23/2/2018 09:20

Danny - also see if you can pick up any f the Financial Times guides - to Investing and to Value Investing. They can be heavy but great reference material. You'll get cheap copies on eBay.The naked trader is another good starting read.

[villarich] 23/2/2018 09:16

Are you and Orrisander for real? Neither of you have posted a single piece of actual analysis on this board. Guessing the days price movements, reposting 3 month old articles and saying the price will hit £30 when the Chinese buy Fevertree is not analysis. I mean prophet analysis - technical like Bamboo or fundamental like I and others have posted in the past. The lack of any real analysis is why people post bile towards and about you. It's grating, it's boring and it adds no value. If you want it to stop then I suggest you stop posting your daily targets, open the Fevertree accounts and do some actual research. Oh and by saying you got a daily price target right once is bragging. Even a broken clock is right twice a day.